When talking to Dianne, she stressed the importance of seeing a product through the entire cycle of trials.  I think she said something like it doesn't make sense to even start until you have the funds to see it through.  That's why we're moving ahead with the ART and 154 is back on the table.  Who knows how many trials and at what cost.  If the first is ~$300k the next one could be twice as much.  Throw in payoff's errr....FDA fee's, lawyer fee's, and a company could burn up cas pretty quick.